Bodycote H2 2025 Earnings Report

Bodycote EPS Results

• Actual EPS: GBX 44.40
• Consensus EPS: N/A
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Bodycote Revenue Results

• Actual Revenue: N/A
• Expected Revenue: N/A
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Bodycote Announcement Details

• Quarter: H2 2025
• Date: 3/11/2026
• Time: Before Market Opens
• Conference Call Date: Wednesday, March 11, 2026
• Conference Call Time: 5:30AM ET

The leading provider of heat treatment and specialist thermal processing services worldwide. Heat treatment encompasses a variety of techniques and specialist engineering processes which improve the properties of metals and alloys and extend the life of components and is a vital part of any manufacturing process. Bodycote (LON:BOY) is uniquely placed via our global network and the experience and knowledge of our people to offer high quality, reliable and cost-effective services to manufacturers whatever their size or market sector.

Bodycote H2 2025 Earnings Call Transcript

Key Takeaways

• Positive Sentiment: Executives highlighted active portfolio reshaping under the Optimise programme — including the sale/closure of multiple sites — and target increasing Specialist Technologies to 35–40% of the portfolio by 2028 with a planned full run‑rate saving of at least £15m by mid‑2026.
• Neutral Sentiment: FY25 delivered broadly stable core organic revenue (‑0.3%) with stronger H2 momentum, but core margin fell ~160bps to 16.8% and adjusted EPS declined to £0.444; cash conversion remained healthy at 78% and the full‑year dividend was held at £0.23.
• Negative Sentiment: Energy and oil & gas were material headwinds — group oil & gas/project activity in Specialist Technologies fell ~40% and energy‑related revenues were down around 25%, removing high‑margin work and pressuring divisional profitability.
• Positive Sentiment: Management reported strong end‑market momentum in Aerospace & Defense (significant H2 acceleration) and industrial gas turbines, which they expect to drive a return to core organic growth and margin expansion in 2026.
• Positive Sentiment: Capital allocation balances growth and returns — an additional £80m buyback announced (to complete by end‑2027), leverage at ~0.6x provides M&A firepower, and bolt‑on deals (e.g., Spectrum, Lake City) plus a >50‑target pipeline support targeted expansion.

Presentation

[Jim Fairbairn, CEO at Bodycote]

Good morning, everyone. Thanks for joining us for the 2025 Bodycote full year results. I'm Jim Fairbairn, CEO, and with me is our CFO, Ben Fidler. I'm gonna give some brief introductory remarks that will set the context and give some highlights. I'll then pass to Ben to go deeper into financials. I'll then come back and talk about the important progress that we've made on the strategy, how we're positioned, and how we see the outlook. You'll remember we set out to firstly build a quality extended leadership team. Secondly, significantly reposition and restructure the business. Thirdly, deploy from our capital markets day, which, as you'll recall, was focused on optimizing the quality of our business, performance and growth.

[Jim Fairbairn, CEO at Bodycote]

In conditions which were challenging in some of our end markets, we've delivered a significant amount last year. In terms of the highlights, revenue momentum improved in the second half. More of that in a second. The most important to me is the quality of the portfolio. We've been executing at pace. We've sold 10 sites in France, closed a further 8 sites, and also made a strategic aerospace acquisition on the East Coast of the U.S. This is a first sign of more bolt-on acquisitions to come. On top of that, our balance sheet remains healthy. Today, we're able to announce a further GBP 80 million buyback that we expect to complete by the end of 2027.

[Jim Fairbairn, CEO at Bodycote]

All of that puts us in a position for 2026, where we expect to drive core organic growth, margin growth, and further drive the strategy for the medium term. As we flagged last year, we saw improved momentum in the second half, and that was primarily led by aerospace. Core revenue, although flat for the year, was up 3% in the second half. In Aerospace & Defense, growth accelerated throughout the year, and it was up 14% in the second half. We saw good growth in aero HIP and in engine parts. Industrial and automotive both remained challenging. Both improved in the second half, but were modestly down year-on-year. North America was more resilient in auto, but softened in industrial later in the year. Europe was the opposite.

[Jim Fairbairn, CEO at Bodycote]

Weak in auto all year, but the comps became easier in industrial. In energy, we saw a significant decrease in available oil and gas work, as well as customer-driven project delays. This has led to around a 25% reduction in revenues. Industrial gas turbines, on the other hand, was up 6%, and we expect further strong order growth this year. Despite that backdrop, there is a really important point that I want to emphasize. What we've done and are continuing to do is to increase the quality of the portfolio. We are laser-focused, through a combination of targeted organic investment and also bolt-on acquisitions, as well as closures and disposals, through the Optimise programme.

[Jim Fairbairn, CEO at Bodycote]

The chart on the left shows that we'll take Specialist Technologies from around a quarter to around 1/3 of the portfolio post-Optimise. Our further growth focus is in all three of the technologies through organic capacity investment and also regional expansion. Our target is to get Specialist Technologies to 35%-40% by the end of 2028. On the right, the chart shows our faster growth markets. These include Aerospace & Defense, medical, IGT. This will reach 45% post-Optimise, and we expect these markets to become the majority of the portfolio by 2028. This stronger foundation gives us the confidence for this year and also the medium term. I'll talk more about this later. With that, I'll pass to Ben.

[Ben Fidler, CFO at Bodycote]

Well, thank you, Jim, and just to add my welcome to Jim's. Thanks for joining us this morning. I'm now gonna spend a little bit more time stepping through in some more detail the key elements of our financial performance for 2025, and also touch on some of the more specific points about our 2026 guidance and outlook. Let's start on this slide with the key highlights of the numbers. As you heard from Jim, in mixed end markets, we delivered broadly stable core revenues for the year down 0.3% organically. As Jim outlined, though, we did see a much stronger level of organic revenue momentum in the second half of the year than we did in the first half.

[Ben Fidler, CFO at Bodycote]

Core margins, you can see here, down 160 basis points to 16.8%, but still a good level. Again, a decent improvement in margins in the second half compared to the first half. Reflecting the lower operating profit and the higher tax rate, EPS fell to GBP 0.444. Cash conversion remained very healthy at 78%, despite a significant increase in the amount of CapEx compared to 2024. Finally, the balance sheet remains in good shape with leverage close to the lower end of our target range. Leverage at 0.6x at the end of December, whilst having returned GBP 100 million to shareholders through a combination of circa GBP 40 million in dividends and GBP 60 million in share buyback. Now diving into the numbers in a little bit more detail for you.

[Ben Fidler, CFO at Bodycote]

Firstly, focusing on the ongoing core business. Core revenues, you can see in the top table here, broadly stable, down 0.3% organic. That reflected a modest fall in volumes, offset partially by increased pricing. Reflecting the market environment, along with mix headwinds, core operating profit fell by 8.5% to GBP 113 million. That's that margin of 16.8% we saw in the last slide. Secondly, in the lower table, if you look through the group lens, so including those non-core activities in the non-core division, revenues were GBP 727 million, down just over 2% organically. Group operating profit, GBP 114.3 million, which equates to a margin of 15.7%, down 130 basis points.

[Ben Fidler, CFO at Bodycote]

Adjusted EPS down 8.6% to GBP 0.444. A few dynamics going into that. Clearly, number one, the lower level of operating profit, modestly higher financing costs as leverage went up, and an increase in tax rate. Of course, those were partially offset by the lower share count from the share buyback execution. Despite the lower EPS, full-year dividend was held at GBP 0.23, continuing our 38-year track record of maintaining or growing the group's dividend. Next, I want to look at a high-level in terms of the key drivers of our operating profit performance in 2025. Now I'm gonna cover the specifics behind the divisional detail on the next couple of slides, so I'll try not to duplicate. As you can see here, divisional profit fell a combined GBP 12.8 million. What was behind that?

[Ben Fidler, CFO at Bodycote]

That reflected the lower oil and gas volumes in specialist technologies and the weak industrial and automotive environment, primarily in precision heat treatment. Non-core profit, as you can see here, was GBP 2.2 million lower. That very much reflected just the execution as we closed sites and as we disposed of those French businesses in November. We're now over halfway through the Optimise actions. That program is going really well. The benefits from Optimise ramped up in line with our expectation, and I think in line with your expectations as well, with GBP 4 million delivered in the year. Mostly in the second half, we delivered about GBP 1 million in the first half. These benefits, where do you see them? You see them partly in the central costs on this chart, and you also see them buried within the precision heat treatment divisional performance.

[Ben Fidler, CFO at Bodycote]

They probably split roughly 50/50 between the two. Finally, FX had just under a GBP 2 million headwind profit, primarily on movements on the euro and the US dollar. Let's now delve into the performance of each of the two core divisions in a little bit more detail. Firstly, Specialist Technologies, where performance in 2025 very much reflected and was shaped by the weakness in the oil and gas markets, where revenues, oil and gas revenues in Specialist Technologies were down 40%, impacted by the end of significant customer project work. This saw revenues in the division, you can see here, fall 3.7% to GBP 212 million. If you exclude that oil and gas effect, underlying Specialist Technologies revenue is up 2%.

[Ben Fidler, CFO at Bodycote]

Trading momentum in this division was much improved in the second half, both in terms of revenue and in terms of operating margin. What drove that was very much led by Aerospace & Defense, which saw a significant acceleration in the second half and up almost 15% for the year in the Specialist Technologies division. Industrial and auto, worth mentioning, they are much smaller parts of this division, but these were challenging markets in the year. Margins were lower, really impacted by the fall in the very high gross margin oil and gas project work that we experienced. With margins at 27.1%, we think still at a very good level and clearly will improve from here as we look forward. Looking forward to 2026 for this division, we'll see a return to organic growth.

[Ben Fidler, CFO at Bodycote]

As the year-on-year oil and gas headwind abates, we expect continued good growth in Aerospace & Defense and industrial gas turbines, and as we also start to see some of the revenues on some of the new investments that we've been making over the last few years in Specialist Technologies ramp up. Next, turning to precision heat treatment. On an organic basis, revenues were up 1.3% to GBP 459 million, with growing volumes of industrial gas turbine work within the energy segment and accelerating growth in aerospace, also seen here in the second half of the year. As Jim mentioned earlier, automotive and industrial end markets remain challenging, with some marked differences between the different geographies, Europe versus North America. Although comparators did ease as we went through the second half for both of those end markets.

[Ben Fidler, CFO at Bodycote]

We took a number of actions to manage the cost base, but reflecting the weak industrial and auto market backdrop, margins in PHT fell by 150 basis points to 16%. Now, as we look forward to 2026, we do expect precision heat treatment to capitalize on further good growth in aerospace and good growth in industrial gas turbines. Although auto and industrial markets are probably likely to remain challenging. The group delivered robust cash flow with adjusted operating cash flow, you can see here GBP 88.6 million. That was lower year-on-year, but that reduction reflected two real things. Firstly, the lower level of operating profit, and secondly, the increased level of capital expenditure as we invest to drive growth in our target strategic end markets and our target strategic processes. Overall operating cash conversion was still healthy at 78%.

[Ben Fidler, CFO at Bodycote]

Restructuring spend, you can see here below the operating cash flow line, rose materially to just over GBP 14 million. That was expected and reflects the ongoing delivery and execution on the Optimise programme. Now, of course, that number excludes the GBP 19 million of disposal proceeds on the sale of the French auto and industrial sites, which is reported below the free cash flow line. Put it all together and overall that left free cash flow at GBP 47.5 million, with year-end net debt at GBP 105 million, leverage at a very comfortable level still.

[Ben Fidler, CFO at Bodycote]

That kind of leads us on to the next slide, where what we've tried to do here is give you some more detail and a little bit of a broader picture as to how we think about capital allocation, how it fits with our strategy, and how we have used it and will continue to use it to drive shareholder value. Let's move clockwise, starting at the top right-hand corner. Firstly, the Optimise programme. Investing in the near term to deliver and execute on the program is progressing really well and is creating, no doubt about it, a better quality Bodycote. Additionally, it's also released some capital through that disposal of the French sites, which we then redeployed and recycled into other parts of the business that are more aligned with our go-forward strategy. Secondly, driving continuous improvement through the Perform program.

[Ben Fidler, CFO at Bodycote]

You'll hear more from Jim on that shortly. It is starting to ramp up, and we've got good level of confidence and conviction that that will deliver meaningful financial benefits to the group over the next three to five years. Thirdly, we continue to invest selectively and with discipline to deliver the strategy, increasing the focus we have on our target strategic end markets, aerospace, industrial gas turbines, medical, and in specialist technologies, and at the more differentiated end of precision heat treatment. That is gonna be through a combination of organic growth as well as M&A, and where we are building the pipeline nicely. Finally, shareholder returns. Last but not least. A blend of regular dividends and additional shareholder returns as and when appropriate with a GBP 100 million return to shareholders last year through this, and you've seen today a new GBP 80 million buyback program announced.

[Ben Fidler, CFO at Bodycote]

All of which continues to be supported and enabled by Bodycote's strong balance sheet. We've got leverage headroom to allow us to execute on all of these priorities for capital allocation and by using them all selectively and carefully to drive growth, improve the quality of Bodycote, and deliver returns to shareholders. Finally, the long-awaited technical guidance slide. I know results season wouldn't be complete without it. Just a few points that I'll draw out from this, as you build your models and build out your forecast for 2026. Firstly, FX. Based on current rates, probably a small positive impact on revenue, very little impact, probably no impact on profit. Secondly, for non-core, bear in mind you've got the disposal of the French sites together with ongoing closures that mean non-core revenues are gonna fall quite significantly in 2026.

[Ben Fidler, CFO at Bodycote]

Thirdly, CapEx, we're gonna continue to invest selectively and with discipline, but we will be investing more as we want to drive growth in those right areas of the business. As we continue with the buyback, share count will reduce. You can see the numbers here. Interest costs probably modestly increase. Finally, as I think many of you have already seen from some of our detailed guidance comments in the release, 2026 will be a year for return to core organic revenue growth and margin expansion. As you model margins, do bear in mind that variable pay could create a headwind of potentially up to 100 basis points in 2026 as this returns to more normalized levels after what has been a relatively low level in 2024 and in 2025. With that, I'll hand back to Jim.

[Jim Fairbairn, CEO at Bodycote]

Thank you, Ben. In terms of the strategy we're executing at pace, 2025 was an important year for milestones in all of the Optimise, Perform, and Grow. Let me talk you through where we are. Optimise actions are increasingly behind us. We successfully carried out this major footprint rationalization, and it's already delivering financially and in line with expectations as Ben said. We're dialing up focus on Perform and Grow. As you'll recall, Perform was actually designed to improve performance, productivity, customer experience, and profitability, and it also improves the foundation for growth. I'm very pleased with the progress in 2025, and it's also great to see the teams so engaged in this area. With Grow, we are focused in multiple areas.

[Jim Fairbairn, CEO at Bodycote]

Internally, we've increased our commercial capability and also resources, and we've realigned our market-facing business development areas to maximize customer opportunities. Additionally, we are investing significantly for future organic growth mainly in the U.S. and Southeast Asia in our most attractive end markets. Let me take you through each in more detail. With Optimise, I couldn't be happier with the approach and the execution of the team. You can see from the timeline, overhead reductions are almost complete. We're over halfway in terms of site consolidations, and we'll have exited 85% of those 21 sites by the end of the year. We've now a successful playbook for this activity including ensuring we retain the revenues that we want if needed again.

[Jim Fairbairn, CEO at Bodycote]

As Ben said, the financial cost-saving benefit last year was around GBP 4 million. We expect around the same again this year in incremental benefit with a full run rate benefit of at least GBP 15 million by the middle of next year. As I mentioned, around 10% of our sites in 2025 had some kind of a lean or productivity improvement pilot. Here's one example of the many pilot projects. This is our Hebron site in Cincinnati. It's a surface treatment site, and it does a lot of IGT work. They are growing, and they're also running out of space. We completed a four-day Kaizen event Q4 last year. Kaizen events are very intensive in short-term workshops that problem solve a specific process issue.

[Jim Fairbairn, CEO at Bodycote]

In this case, it was the transportation of parts. Travel per week in parts was reduced by 5 mi. This obviously meant a reduced lead time through less process crossovers, therefore giving more capacity for growth. What you see on the chart is the before and after flow, and you see a far less complexity and an easier platform for growth. We also had observers from different sites there, and it's also created a momentum from the event. It's now created a pull factor for other sites. I should actually reiterate that success in this area is hundreds of small incremental improvements that add up, and you also develop a problem-solving muscle, and you create a culture of continuous improvement. From that, you drive productivity, differentiation, growth, and also a competitive advantage.

[Jim Fairbairn, CEO at Bodycote]

It's a well-worn path. We've always had some elements of best practice within Bodycote. It just wasn't coordinated, and it certainly wasn't part of our culture. On the left, you can see some elements of the pilot program. We've a toolbox to train people on. I talked about Kaizen events. We've also simplified some of our productivity metrics. The right side shows our progress. We are 60% complete in terms of foundational work, and we've spent a lot of time with our plant managers training and developing them. We are ramping it up this year. We've just recruited new regional capability.

[Jim Fairbairn, CEO at Bodycote]

I talked about the pull factor we've got, you know, from the other sites, and we're developing four lighthouse sites, two in North America and two in Europe, with the full suite of tools. These projects are actually really important. We are on track to deliver a margin improvement of 100 basis points from Perform by the year 2028 and more thereafter. Let's come on to how we drive faster growth. Last year, we spent a lot of time laying out the foundations to drive faster growth in the next few years. Of the five columns on the chart, the first two are linked. We've looked at the way that we're structured, in particular the sales structure.

[Jim Fairbairn, CEO at Bodycote]

We've looked at the way we work across divisions, and we've done a fundamental reboot. We've improved sales capability. We've set up cross-divisional groups, such as one on European defense, and we've challenged our general managers to drive new growth. The middle column is all about growth investments. I'll talk about that on the next slide. The right two columns are accelerants to the strategy. I'll cover both in the next few slides. All of this together will enable us to deliver our goal of mid-single digit growth through the cycle. Let me give you some more tangible growth examples. Across these projects, we're investing more than $60 million between 2025 and 2026. Firstly, the new S3P expansion in South Korea.

[Jim Fairbairn, CEO at Bodycote]

It's the first time we've taken this outside the Western areas of Europe and North America, and we go live in the second half of the year. We will service the Korean, the Japanese, and the Chinese markets from this site and with the room in the site to develop it even further. The second one is we're adding new HIP capacity in the U.S. and also in France. The picture you can see is from Greenville, South Carolina, which is now a multipurpose aerospace site where we're targeting the growing additive market. The third example here is we are moving two aerospace sites that were frankly substandard. Both also have significant growth potential. One is in Cincinnati, and the other one is in Los Angeles.

[Jim Fairbairn, CEO at Bodycote]

Fourthly, our two Mexican automotive sites are close to full. In the north of the country, we're putting in, like, a new plant which will meet the rising demand of our supply chain. These are just some examples that gives us the short and medium-term confidence in growth, and we expect to see revenue growth from all of these projects by the end of the year. Our first accelerant is sustainability. As I've said before, you'd expect us to drive energy efficiency. This is even more important than ever. We've made more progress in 2025. In fact, we've driven energy intensity, that's energy usage against revenues, down by over a quarter in the last five to six years.

[Jim Fairbairn, CEO at Bodycote]

Energy focus is a large theme in our general manager conferences. On the right, the chart shows our activities on the drivers of outsourcing from our customers. We have some new offers now. For example, we've now five net zero sites, and all of these broadens our proposition to our customers. We've built a solid pipeline of sustainability opportunities, and we're looking to make progress on this in 2026. Sustainability remains one of our important strands of our growth strategy. I'm very happy with the progress that we're making in M&A. Ben talked about the importance of recycling capital. We highlighted the French disposal that completed a few months ago. In January, we were pleased to announce the acquisition of Spectrum.

[Jim Fairbairn, CEO at Bodycote]

I actually visited the site as a part of the diligence process, and it's a great small business with a great team, and it also gives us access to some new aerospace supply chains. We're actively working our funnel and have a number of opportunities at different stages of development. Our aim is to add small and medium-sized bolt-ons that are aligned to the strategy of improving our portfolio. Coming to outlook. This year, we expect to return to organic core growth. That will be led by strong growth in Aerospace & Defense and in IGT. I couldn't be happier with the team and their focus there. We expect industrial and particularly auto to remain challenging. Clearly, there is a subdued economic backdrop and macro environment in geopolitical uncertainty.

[Jim Fairbairn, CEO at Bodycote]

We'll deliver improvement in operating margins through volume growth, better mix, and our self-help work. All of that means that we'll drive strategic progress, keeping the momentum to deliver a high-performing, resilient, and faster-growing Bodycote. We also remain confident in our medium-term financial targets. With that, we'll open up to questions. If you're in the room, if you could raise your hand, and online, please post your question. Thank you. Andy, we'll start with you, if you don't mind.

[Analyst at Jefferies]

Of course. Good morning, gents. Thank you for the presentation. I've got loads of questions, but I'll start with three, and then I'll come back if the other ones haven't been answered. Firstly, could we just talk about the Middle East, your exposures there, if you can just remind me where you're positioned and where you play? I appreciate it's difficult, but any kind of early thoughts on how you're responding to what is currently a difficult situation? You talked about very briefly, Jim, for the second question on M&A. The buybacks, you know, are reasonably self-explanatory, but just wanna understand kind of the narrative around buybacks and M&A.

[Analyst at Jefferies]

If you can maybe just go into a bit more detail about the funnel and how that's progressed over the last, I guess, 12 months, quality, size, you know, any thoughts on pricing. And then last but not least, probably one for Ben. Energy, my understanding is you're pretty well hedged from an energy perspective given what's going on with oil prices and broader energy prices. Can you just remind me, A, where you're up to on that, and B, the broader policy for the group?

[Jim Fairbairn, CEO at Bodycote]

Well, I'll kinda start, Ben can maybe take energy and the buyback. In terms of the Middle East, our direct sales there are only 1% of our portfolio. We don't have any, you know, infrastructure. We don't have any people. We don't have any plants, you know, in that area. Thankfully, that is our position. You know, in terms of the internal way that we'll look at that, I mean, you'll know that energy cost is around 10% of our revenue. It's about GBP 70 million. Just to put it in context, labor is 40%. You know, I'll say this before Ben says it. Ben and the team have done an amazing job at being more intentional and also structured around energy hedging.

[Jim Fairbairn, CEO at Bodycote]

Certainly, for the next two quarters, we're in really good shape. We're very pleased with that. Ben can go into some of that detail. Then, obviously, it's actually well known that we've managed, you know, significant energy spikes through surcharges previously. Now, we do surcharges all the time. It's not just energy surcharges. Like, for example, in Los Angeles, we do environmental surcharges that are passed on, et cetera. So we have a well-oiled process around surcharges. We still actually do some energy surcharges now. So we will take the right decision on actually how we manage that, you know, going forward. I'll briefly talk about M&A, and then pass to Ben.

[Jim Fairbairn, CEO at Bodycote]

You know, in terms of M&A, Spectrum, I mean, really was the first acquisition that the new team were involved in. Lake City was finished just before I joined the company. I think the integration of Lake City has gone fantastically well. Couldn't be happier with that. I really liked what I saw at Spectrum. It's a very small acquisition. You know, in terms of, you know, over 80% aerospace defense opens up Pratt & Whitney supply chain. We're very happy with that. It's a great team, and it's already fitted. So the plumbing aspect within Spectrum is already in place. In fact, the new general manager there was at the general manager conference at Dallas we had last month, and he fully engaged.

[Jim Fairbairn, CEO at Bodycote]

You know, it's as though that they've been there, you know, a long time. That's very positive. I think in terms of Spectrum, $8 million, Lake City, $50 million, I think we have a range of targets, you know, between these two bookends. Certainly as we look at the funnel, we've got over 50 targets at various phases within the funnel. Some at the top end of the funnel. We're very focused in terms of wanting to do more acquisitions as a part of our balanced capital allocation that Ben will talk to in a minute. You know, it's a huge focus. In fact, we've just recruited a consultant, you know, to help us in terms of Aerospace & Defense.

[Jim Fairbairn, CEO at Bodycote]

Yeah, I'll pass to you, Ben.

[Ben Fidler, CFO at Bodycote]

Just picking up on a couple of those with a little bit more color, but you've given you know a good picture, Jim. Thank you. On hedging, you know, we're very pleased with the level of cover we've got for the next two quarters. It does start to tail off as we go through the fourth quarter. Typically, in a business like this, we haven't got much hedge cover for 2027, but that is intentional actually. We don't want to be over-hedged in the future. That can create problems in and of itself. What I would add is a bit more color on the hedging that we have for the next two quarters. If anything, we have a much higher bias to that hedging in Europe than we do in North America.

[Ben Fidler, CFO at Bodycote]

Sometimes you've maybe got to be lucky as well as being smart. I'll take either. That does leave us in a better position, certainly where we're seeing the big spikes in European gas prices and no doubt electricity prices. Let's see how long the conflict goes on for. As Jim mentioned, we have used surcharges in the past to protect our economics as a business. It's never easy to put pricing up to customers. It's very much let's wait and see how things develop over the next few weeks. It's something we're monitoring very closely as to whether we may need to revisit doing that to protect our economics.

[Ben Fidler, CFO at Bodycote]

I think on your second question about the narrative around both the buyback and M&A, what would I add to what Jim has said? Look, what we want to do is we want to grow the business. We want to prosecute and execute the strategy of not just growing the business, but growing the business in the areas that are more differentiated, higher growth, specialist technologies, aerospace, industrial gas turbines, medical, et cetera. At the same time, we're very mindful of wanting to manage rightly for shareholders, the risk/reward balance, which argues to some extent a share buyback and the attraction of a share buyback at the valuation that we're at today as well. We are wanting to do all of those three things and balance all of those three things.

[Ben Fidler, CFO at Bodycote]

What I'd also add is that with leverage at 0.6x, you can do the math. If our target is within a range of 0.5x-1.5x, that additional circa one turn of leverage gives us a little bit more than GBP 200 million of firepower to do stuff with. That gives us more than adequate capacity to do this GBP 80 million buyback and to give us a good pool of funding to execute on M&A. Of course, the business is gonna be generating free cash flow over that two-year period as well. We do believe it genuinely gives us optionality to do all of these three things with hopefully the right balance.

[Jim Fairbairn, CEO at Bodycote]

Jonathan, you wanna?

[Analyst]

Good morning. Hi, it's Jonathan Barki. I just have two questions, please. The first one was just on industrial gas turbines and the outlook there. Can you just sort of talk us through just in terms of what you're seeing or how much revenue visibility you have within that business? Do you feel that you'd need to add capacity to sort of service the forthcoming demand? And also, is there opportunities within that business or within industrial gas turbines to push your Specialist Technologies further into that than it currently is? And then the second question was just in terms of the Optimise and the remaining GBP 11 million of benefits to come through. How does that spit out? Is that half of that again go into the central cost charge, the other side go through into precision heat treatment? Thanks.

[Jim Fairbairn, CEO at Bodycote]

Okay, I'll take the first question, Ben, if you can take. As we said in the prepared remarks, IGT grew 6% in 2024. You know, we expect it'll grow faster. We expect it will grow more this year. Now, there has been a little bit of supply chain constraints, I mean, that we've seen in some of our plants, especially in North America. I referenced the Hebron site there, which is in Cincinnati. It primarily does IGT. We've just actually set up an extension to that facility, primarily for, you know, IGT work. We're doing a lot of both IGT and additive manufacturing related as part of, you know, long-term agreements.

[Jim Fairbairn, CEO at Bodycote]

As we see, you know, the market ramping up and, you know, supply chain constraints easing, then we're confident that we will grow with that. In terms of Spectech, the wider question around Spectech, I come back to how we were very silo-driven in terms of, you know, sales and business development. Internally now, we're actually very different. Between like North America, all the specialist technologies and also the precision heat and Aerospace & Defense, all of that is actually shared within single business development silos now and not individual silos. One of our, like, for example, some customers were complaining we, you know, in a single flow, we had to give them two invoices, which is just like crazy because like one was specialist and one was precision.

[Jim Fairbairn, CEO at Bodycote]

That's all gone. I think internally, we were creating barriers potentially, you know, internally. Certainly when I met some customers at the Paris Air Show, that's what they were telling me. We've tried to really, you know, focus on to make our seamless service. I think we'll start seeing the benefits not just in IGT, but in the wider aerospace space actually this year.

[Ben Fidler, CFO at Bodycote]

Should I pick up the one on Optimise? Yes, you're right. GBP 4 million delivered, GBP 11 million, at least GBP 11 million to go. You saw Jim's chart on the shape and profile of that GBP 11 million to go. GBP 4 million or so this year, probably GBP 4 million-GBP 5 million to deliver in 2027, and then the remaining tail in 2028. Where do those benefits feed in of what is left? I draw you to that, again, the Optimise chart that Jim shared. The majority of the overhead on the timeline, so the majority of the overhead actions are done. There are still some left, not that many. Those that are left are in more the divisions. There's not further overhead action left in central costs. Therefore, there's a bit in the divisions from overhead.

[Ben Fidler, CFO at Bodycote]

The remaining piece of the Optimised benefit is more gonna be driven and felt from the retained revenues and the benefits, the drop-through benefit from where we retain revenues by moving work from a closed plant to another Bodycote plant that is proximal but at much higher drop-through. To state the obvious, that will be in the divisions predominantly in precision heat treatment.

[Jim Fairbairn, CEO at Bodycote]

Yeah.

[Tom Jacob, Managing Director at Deutsche Numis]

Hi, guys. I'm Tom Jacob from Deutsche Numis. I think two topics for me. I think the first one is I just wanna pick up on your comments, Jim, just about the reorganization the business is having in terms of market facing on the business development side. Clearly, there's a concerted effort to leverage the network more fully across the business. You know, should we be expecting to see LTAs rise across the portfolio? Does all this lead to some more formal integration of Bodycote into supply chains of your key strategic customers? You know, thinking about A&D, thinking about IGT as mentioned previously. Some comments on that would be great. The second part of that, which perhaps leads on, is could we extend that into how we're thinking about pricing across the portfolio?

[Tom Jacob, Managing Director at Deutsche Numis]

I think you mentioned tailwinds this year. How far along in the journey do you think you are in terms of valuing the new Bodycote more appropriately given the new capabilities and capacity and value you're bringing?

[Jim Fairbairn, CEO at Bodycote]

Yeah. Okay. Well, I'll kick off. So the first thing, what was obvious as we looked at the, you know, internal makeup of the company in terms of business development sales is we had internal barriers that weren't actually helping us. That was the first way that we looked at things. We weren't really sharing information, you know, across the whole, from a kind of end market point of view, because we've got, you know, technologies and we've got end markets and we've got regions. How you navigate through that, you know, every company's got the same issue. How you navigate through that is either gonna define you or actually not define you. I think that was important. We don't necessarily see a significant increase in LTAs.

[Jim Fairbairn, CEO at Bodycote]

You know, because there is sometimes a trade-off in LTAs, where you want the business, but you're up against, you know, the trade-off is that you can sometimes have to be quite sharp on the pencil in terms, you know, of actually price. I think the price that we saw was that we were potentially missing opportunities through not being through the whole way through the value chain. A part would come into one of our sites, you know, precision heat treatment, and it would go somewhere else. Whereas if actually we can control more of the stages of the process, that's kind of really where the price actually was.

[Jim Fairbairn, CEO at Bodycote]

I'd say that we've been okay at kind of leveraging our network, but we haven't been great at it. Certainly, the new business development and execution organization we've actually put in place realizes that. We've got you know I talked about Greenville being an aerospace center of excellence, so it does you know precision and also HIP, right? Now, that's a minority. We also have other HIP sites that have you know precision heat treat capacity that just weren't really leveraged. We weren't really leveraging our network. I think there is a bigger opportunity here to sweat our our kind of assets you know and also regions where we didn't really fully focus, especially in aerospace rather than you know in IGT.

[Jim Fairbairn, CEO at Bodycote]

I think that will take time to come through, but it is actually part of the growth focus we now actually have within. I think the final thing I would say is that, you know, I start with the team because with a new President of Aerospace, Defense and Energy, who I think some of you met at the Capital Markets Day. She's actually 50% of her team is actually new. We've really top-graded the teams, you know, from my team through the divisional teams. We have really hired, you know, for growth and actually where we're taking the business, which, you know, I couldn't be happier with. Do you wanna talk about pricing?

[Ben Fidler, CFO at Bodycote]

Yes. Look, I think on the pricing piece, look, I mean, pricing, your customers never embrace you with open arms about price increases, or at least not most normal customers. As we move forward, I think, you know, the business historically has a good track record of being able to push through annual price increases. In some years and in some markets, that is harder than in others. Clearly, if we think back to 2025, you know, in automotive and industrial, let's face it was tougher rather than easier. Pricing went up, but it was not an easy discussion. As we move forward, I think there's two aspects around our pricing that I would flag. I suppose at its heart, your ability, any business's ability to price incrementally is supported by differentiation and value add, isn't it?

[Ben Fidler, CFO at Bodycote]

The more differentiated we are, and the more value add we can provide versus our competitors, it puts you in a better position to price. That is also a core part of the strategy. Differentiation doesn't entirely equal specialist technologies, but it does, and it equals the more differentiated ends of precision heat treatment. That is the way the portfolio and the business is increasingly shifting. That will help our pricing bias. Secondly, value add, it comes back to Jim's point about where we can aggregate, leverage, bundle some of our services in a way that some of our smaller standalone competitors who might just provide single processes can't do.

[Ben Fidler, CFO at Bodycote]

Therefore, by being able to do more of that and extracting more of that opportunity, which historically the business has not been as good at as it could have been, I think that we should also help our ability to incrementally price as well as win more volume. Look, I think pricing is never easy. It won't suddenly change, but, you know, history says we can price, and as we execute the strategy, I think it enhances our opportunity and chances there rather than reduces them.

[Tom Jacob, Managing Director at Deutsche Numis]

Thanks.

[Harry Philips, Industrials Analyst at Peel Hunt]

It's Harry Philips at Peel Hunt. Sorry, you're hiding there, Jim. I can't quite see.

[Jim Fairbairn, CEO at Bodycote]

Yeah, yeah.

[Harry Philips, Industrials Analyst at Peel Hunt]

Three questions, please. Just first of all, on the Perform sort of initiative, just trying to get an understanding of, and clearly, you set out the example in Cincinnati about how you've improved flow through the plant. To really get towards that 100 basis point improvement, how much is sort of additional revenue dropping through that improved, more efficient cost base, and how much is cost in its own right, i.e., if there were no growth, what would Perform add?

[Harry Philips, Industrials Analyst at Peel Hunt]

Maybe it's over detailed, but just an idea of the sort of sensitivity. Is it more a cost or more a sort of revenue drop-through aspect? The second is the second half organics, which were pretty punchy, but probably against softer comps in 2024. We're looking into 2025. Is there any reason we should sort of restrain our enthusiasm for sort of running those forward, particularly as the oil and gas sort of balancing item abates? Lastly, on the variable consideration sort of guidance you've given, it'd be quite interesting to know the assumptions you've made. Is that a performance? It'd just be quite interesting to know the assumptions of what drives that. Maybe it'd be in the accounts later, but quite interesting.

[Jim Fairbairn, CEO at Bodycote]

Okay, I'll take the first one, and Ben can take two and three, Harry. Well, thanks for that. You know, Perform is actually really focused on improving productivity and also process efficiency. That's really the nub of it. So you get improvements. You get cost improvements, and I would always say that you should always aim a target at more cost improvements because they're much more certain and in your control. So I usually say that should be 2/3 to three-quarters of the, you know, talking about sensitivities. But if we go back to why we did, you know, Perform in the first place, I think that's important.

[Jim Fairbairn, CEO at Bodycote]

The first thing is, you know, I've now been at 67 sites, and all of them have got something to offer other sites, and it's all different. If we can, you know, aggregate that and look at different, you know, best could be furnace loading, it could be the way that they marshal the visual side of things, and we weren't capturing that. That comes down to either process improvement or productivity, which is really, you know, a function of actual cost. Last year, we hired a new head of continuous improvement, who joined us just before the half year actually. Previous to that, we were running a few pilot programs, but he's this ex, you know, Danaher guy.

[Jim Fairbairn, CEO at Bodycote]

Unbelievable, what he's achieved in six months running full pilot programs, not just in the U.S. We did a couple in France. We did one. Yeah, I think, so we did one in France that reduced our kinda lead time by 40%, just like a single Kaizen event. We haven't done these before. The opportunity plus, you know, all the VP group, you know, which is kinda one below presidents, there was about 23 VPs. They're all. They couldn't be happier getting involved and, like, learning new skills, you know, and capability. I think the final comment I make is it's a methodical rollout. You know, I've been through this, like, so many times.

[Jim Fairbairn, CEO at Bodycote]

People learn something, then they fail on the implementation 'cause they don't really know the subtleties. This is actually why it's a multi-year program. You learn by doing. Actually, you learn by failing, so that, you know, the process actually doesn't really improve. You do it again, and you learn something, and then you build the, you know, skill set around that. I think as I think about it, mainly cost focus, okay, which is good. If we grow, we could get, you know, incremental benefit, not that Ben will allow me to say that.

[Jim Fairbairn, CEO at Bodycote]

We, you know, there's a real momentum here, and we trained everyone at the general manager conference on safety and how we're thinking about safety, quality, delivery, cost, and we're really creating a movement within Bodycote. It takes a long time to roll out. Sorry, it's a bit of an extended answer, but it's just, like, so important that we build this in the company. Sorry. Over to you.

[Ben Fidler, CFO at Bodycote]

No, thanks, Jim. I'll take your question on the second half organics, and I would never wish to stand between you and your enthusiasm, Harry. It's a dangerous place to be. Look, I mean, you're right. First half, -3.5%. Second half, +3.2%. What drove that improvement in the second half in particular? Strong acceleration in Aerospace & Defense. You know, decent growth in our industrial gas turbines, that also picked up in the second half compared to the first half a little bit. Still challenging markets in the second half in industrial and in automotive, particularly U.S. industrial, as you heard from Jim. Oil and gas, that in the second half, was still probably the group level down 20%-25% in the second half.

[Ben Fidler, CFO at Bodycote]

As you roll forwards, you're kind of saying, well, look at our outlook statement, look at where we're steering to individual end markets, and you're kind of saying, well, aerospace, defense, IGT, continuation of those kind of trends. Good growth. Strong growth. Industrial probably remains challenging. Automotive, if you look at global light vehicle production, I think that probably remains quite challenging. The oil and gas feature, which washes through from a comps perspective, certainly once we get to the end of the first quarter, starts to go away. I think that gives you some sort of boundary conditions as to, well, okay, as you fly forwards, what sort of level of organic growth do you think the business might be capable of delivering in 2026. That's gonna be your call. I'm not gonna tell you what number to put in.

[Ben Fidler, CFO at Bodycote]

That gives you some conditions as you look at those end markets. You look at what we delivered in the second half, and you say that oil and gas headwind starts to diminish. It's only 5% or 6% of sales in oil and gas, right? It's nonetheless helpful rather than unhelpful. Your third question, remind me your third question, sorry.

[Harry Philips, Industrials Analyst at Peel Hunt]

Just on the variable consideration, you've sort of put a number in there of

[Ben Fidler, CFO at Bodycote]

Okay.

[Harry Philips, Industrials Analyst at Peel Hunt]

sort of GBP 7 million-GBP 8 million, and it's just to understand if that's sort of formulaic against operational performance.

[Ben Fidler, CFO at Bodycote]

Yes, it is. It's entirely. Well, 80% of it is driven by financial performance in terms of variable metrics. There's 20% of ours for the whole organization where it's driven by your personal performance, but 80% is financial performance. You'll see when the annual report comes out what the level of payout has been, for Jim and I at least, and that trickles down through the organization. Everybody's on the same kind of approach and metrics. What we're saying is for 2026 from a planning perspective, inevitably our planning assumption is we hit our budget. 2025, we did not hit our budget, as you'll see, when the annual report comes out, and that's hardly a state secret in terms of where the numbers landed.

[Ben Fidler, CFO at Bodycote]

Yeah, the headwind, if we hit our budget, that's the 100 basis point of headwind.

[Harry Philips, Industrials Analyst at Peel Hunt]

Sorry, just one very final one. On CapEx, how much of CapEx is maintenance and how much, again, coming back to Perform, how much would be sort of not necessarily just Perform, but you know, growth CapEx for want of a phrase?

[Ben Fidler, CFO at Bodycote]

It probably splits kind of 60-ish% is maintenance, 40% is growth.

[Jim Fairbairn, CEO at Bodycote]

On Perform, there's like minor CapEx. We're looking at some automation projects, but it's, you know, noise around the edges.

[Analyst at Jefferies]

Can I just follow up with a quick?

[Jim Fairbairn, CEO at Bodycote]

Yeah, yeah.

[Analyst at Jefferies]

Quick few questions? It's Andy from Jefferies again. On IGT, are you broadly agnostic to, from a customer base perspective, large versus small, et cetera? Or do you guys play in specific areas or with specific customers? On Perform, two really quick questions. You talked about a $50,000 total cost to implement. Are you able to give us what the benefits were from that spend? Just on the foundational versus advanced in terms of the rollout, from an idiot's perspective, as you know, Ben, it would appear that the foundational bit is, I would say, more standardized, quite straightforward to roll out across multiple plants, yet the advanced is gonna be quite complicated because every plant is different. Does that also bring with it the same amount of benefits?

[Analyst at Jefferies]

i.e., the foundational bit gives you a good start, but the advanced is where you get a majority of that 100 basis points of margin.

[Jim Fairbairn, CEO at Bodycote]

Yeah. It was. Let me take these. In IGT, I mean, we're at the larger end of the IGT range. Without you know, I'm not gonna mention customer names here, but they're household, you know, names. We've got good relationships. In fact, we even do some R&D for some of them. We're. That certainly answers that. You talked about the $50,000 of that cost. That's just, you know, moving machines and just it going about. You know, in terms of actual benefit, the team usually initially within three months, it pays back, you know, and then gathers momentum after that. It's very short.

[Analyst at Jefferies]

$50,000.

[Jim Fairbairn, CEO at Bodycote]

Yeah, yeah. You know, the investment Ben talked about was more about headcount because we've had. We now have regional CI leads. You know, Europe just, they started a few months back and, you know, their purpose is to work with the lighthouse sites and also train the VPs and also general managers. In the lighthouse sites, we're recruiting dedicated CI people as, you know, part of the process, but they'll report into the general manager. There's again a kinda structure there. Very, very quick, you know, payback. In terms of your foundational and advanced, you're absolutely right. Foundational is almost like, you know, a baseline of actually continuous improvement. 5S, you know, making sure that workspaces are actually clean.

[Jim Fairbairn, CEO at Bodycote]

I mean, every shadow boards, everything's to hand. You know, you've got a daily management system, which is safety, quality, delivery, cost. So if an issue comes in and you're problem-solving that. This is just, you know, the baseline stuff, which actually in terms of, you know, safety and some of the quality, delivery and cost, you know, we're actually very advanced, you know, through the whole portfolio. We have, you know, internal targets that I tell the presidents. We should be looking to deliver 1% operating margin per year in, you know, improvement projects. Now, you never hit that, but you've got, you know, enough, you know, initiative, you know, to drive that and there's always, you know, bumps in the road. In terms of, you know, advanced stuff, that's where you.

[Jim Fairbairn, CEO at Bodycote]

We'd look at error proofing. It's called Poka-Yoke, which is not a joke. We'd look at error proofing. You'd look at like changeover times. You know, you'd look at different ways. You'd look at where you can really have advanced visual management. Like they call them like water spiders, you know, where someone actually comes in and moves stuff around, you know, stations because of the condition of like a visual representation. These are all advanced stuff, and they'll all be in the Lighthouse pilot programs. We've got the team that can deliver that. Any other questions in the room? Yep.

[Analyst]

With regards to your Aerospace & Defense sector, end market, do you see yourselves growing alongside delivery numbers for Boeing and Airbus, or can you grow above those numbers, for this coming year?

[Jim Fairbairn, CEO at Bodycote]

Yeah, I mean, what we're guiding to, obviously, last year, aerospace actually grew 8%, and so what we would say is that we're looking, you know, high single digit, low double digit in both Aerospace & Defense. That's our, you know, guidance. I think some of the numbers that I've seen on deliveries are slightly higher than that, I think, from what I remember. But that would be the level that we'd actually look to guide it. You know, it's never a straight line year-on-year. We hear about different supply chain congestion. We talked about it in IGT earlier. There's still some in aerospace. That I think we're comfortable, you know, talking about that.

[Analyst]

Is that volume growth or volume and price?

[Jim Fairbairn, CEO at Bodycote]

Uh-

[Analyst]

that single digit.

[Jim Fairbairn, CEO at Bodycote]

Volume growth.

[Analyst]

Volume growth.

[Jim Fairbairn, CEO at Bodycote]

Yeah. Yeah.

[Ben Fidler, CFO at Bodycote]

The other dimension, just to feed into that, is for our aerospace business, it's more exposed to original equipment and therefore OEM build rates. Your question is kind of a very good question. It's probably about 60% OE and about 40% that's driven by the aftermarket. You know, you've got to look at it through the blended sort of average of both of those, together.

[Jim Fairbairn, CEO at Bodycote]

With that, we'll call the meeting to a close. Thanks very much. Thank you.

[Ben Fidler, CFO at Bodycote]

Thank you.

Participants

Executives

• Ben Fidler, CFO
• Jim Fairbairn, CEO

Analysts

• Harry Philips, Industrials Analyst at Peel Hunt
• Tom Jacob, Managing Director at Deutsche Numis
• Analyst
• Analyst
• Analyst at Jefferies